153 related articles for article (PubMed ID: 35301949)
21. Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma.
Flecken T; Schmidt N; Hild S; Gostick E; Drognitz O; Zeiser R; Schemmer P; Bruns H; Eiermann T; Price DA; Blum HE; Neumann-Haefelin C; Thimme R
Hepatology; 2014 Apr; 59(4):1415-26. PubMed ID: 24002931
[TBL] [Abstract][Full Text] [Related]
22. Immunotherapeutic strategies for treatment of hepatocellular carcinoma with antigen-loaded dendritic cells: in vivo study.
El-Ashmawy NE; El-Zamarany EA; Khedr EG; El-Bahrawy HA; El-Feky OA
Clin Exp Med; 2018 Nov; 18(4):535-546. PubMed ID: 30062618
[TBL] [Abstract][Full Text] [Related]
23. Characterization of metastatic tumor antigen 1 and its interaction with hepatitis B virus X protein in NF-κB signaling and tumor progression in a woodchuck hepatocellular carcinoma model.
Li YT; Liu CJ; Su TH; Cheng HR; Jeng YM; Lin HL; Wang CC; Kao JH; Chen PJ; Chen DS; Wu HL
Oncotarget; 2016 Jul; 7(30):47173-47185. PubMed ID: 27323415
[TBL] [Abstract][Full Text] [Related]
24. Application of cancer-testis antigens in immunotherapy of hepatocellular carcinoma.
Seifi-Alan M; Shamsi R; Ghafouri-Fard S
Immunotherapy; 2018 Apr; 10(5):411-421. PubMed ID: 29473472
[TBL] [Abstract][Full Text] [Related]
25. Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma.
Mizukoshi E; Yamashita T; Arai K; Sunagozaka H; Ueda T; Arihara F; Kagaya T; Yamashita T; Fushimi K; Kaneko S
Hepatology; 2013 Apr; 57(4):1448-57. PubMed ID: 23174905
[TBL] [Abstract][Full Text] [Related]
26. Protein glycosylation alterations in hepatocellular carcinoma: function and clinical implications.
Wang Y; Chen H
Oncogene; 2023 Jun; 42(24):1970-1979. PubMed ID: 37193819
[TBL] [Abstract][Full Text] [Related]
27. Role of Immunity in Pathogenesis and Treatment of Hepatocellular Carcinoma.
Schmidt N; Thimme R
Dig Dis; 2016; 34(4):429-37. PubMed ID: 27170398
[TBL] [Abstract][Full Text] [Related]
28. Immunodiagnostic Biomarkers for Hepatocellular Carcinoma (HCC): The First Step in Detection and Treatment.
Xing M; Wang X; Kiken RA; He L; Zhang JY
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34200243
[TBL] [Abstract][Full Text] [Related]
29. Current Strategies for Modulating Tumor-Associated Macrophages with Biomaterials in Hepatocellular Carcinoma.
Liu Q; Huang W; Liang W; Ye Q
Molecules; 2023 Feb; 28(5):. PubMed ID: 36903458
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapy of Hepatocellular Carcinoma.
Heinrich B; Czauderna C; Marquardt JU
Oncol Res Treat; 2018; 41(5):292-297. PubMed ID: 29705790
[TBL] [Abstract][Full Text] [Related]
31. Dynamic and specific immune responses against multiple tumor antigens were elicited in patients with hepatocellular carcinoma after cell-based immunotherapy.
Han Y; Wu Y; Yang C; Huang J; Guo Y; Liu L; Chen P; Wu D; Liu J; Li J; Zhou X; Hou J
J Transl Med; 2017 Mar; 15(1):64. PubMed ID: 28330473
[TBL] [Abstract][Full Text] [Related]
32. Human dendritic cells genetically engineered to express high levels of the human epithelial tumor antigen mucin (MUC-1).
Henderson RA; Nimgaonkar MT; Watkins SC; Robbins PD; Ball ED; Finn OJ
Cancer Res; 1996 Aug; 56(16):3763-70. PubMed ID: 8706022
[TBL] [Abstract][Full Text] [Related]
33. Potential therapeutic value of dendritic cells loaded with NY‑ESO‑1 protein for the immunotherapy of advanced hepatocellular carcinoma.
Chen Y; Huang A; Gao M; Yan Y; Zhang W
Int J Mol Med; 2013 Dec; 32(6):1366-72. PubMed ID: 24085111
[TBL] [Abstract][Full Text] [Related]
34. Immunotherapy of hepatocellular carcinoma.
Korangy F; Höchst B; Manns MP; Greten TF
Expert Rev Gastroenterol Hepatol; 2010 Jun; 4(3):345-53. PubMed ID: 20528121
[TBL] [Abstract][Full Text] [Related]
35. Structurally defined synthetic cancer vaccines: analysis of structure, glycosylation and recognition of cancer associated mucin, MUC-1 derived peptides.
Liu X; Sejbal J; Kotovych G; Koganty RR; Reddish MA; Jackson L; Gandhi SS; Mendonca AJ; Longenecker BM
Glycoconj J; 1995 Oct; 12(5):607-17. PubMed ID: 8595249
[TBL] [Abstract][Full Text] [Related]
36. Engineering T cells for immunotherapy of primary human hepatocellular carcinoma.
Caraballo Galva LD; Cai L; Shao Y; He Y
J Genet Genomics; 2020 Jan; 47(1):1-15. PubMed ID: 32089500
[TBL] [Abstract][Full Text] [Related]
37. Adaptive immunity in hepatocellular carcinoma: prognostic and therapeutic implications.
Fatourou EM; Koskinas JS
Expert Rev Anticancer Ther; 2009 Oct; 9(10):1499-510. PubMed ID: 19828011
[TBL] [Abstract][Full Text] [Related]
38. Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma.
Korangy F; Ormandy LA; Bleck JS; Klempnauer J; Wilkens L; Manns MP; Greten TF
Clin Cancer Res; 2004 Jul; 10(13):4332-41. PubMed ID: 15240519
[TBL] [Abstract][Full Text] [Related]
39. Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies.
Giraud J; Chalopin D; Blanc JF; Saleh M
Front Immunol; 2021; 12():655697. PubMed ID: 33815418
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies.
Hoseini SS; Cheung NV
Cancer Lett; 2017 Jul; 399():44-52. PubMed ID: 28428075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
